Athenex (FRA:2MT0) EPS (Basic) : €-15.07 (TTM As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex EPS (Basic)?

Athenex's basic earnings per share (Basic EPS) for the three months ended in Dec. 2022 was €-4.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2022 was €-15.07.

Athenex's EPS (Diluted) for the three months ended in Dec. 2022 was €-4.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was €-15.07.

Athenex's EPS without NRI for the three months ended in Dec. 2022 was €-3.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2022 was -14.89.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Athenex EPS (Basic) Historical Data

The historical data trend for Athenex's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex EPS (Basic) Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

-32.00

-30.06

-28.28

-34.02

-14.93

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EPS (Basic)	Get a 7-Day Free Trial															-16.82	-2.91	-5.30	-2.83	-4.04

Athenex EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Athenex's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-97.635	-	0)	/	6.541
	=	-14.93

Athenex's Basic EPS for the quarter that ended in Dec. 2022 is calculated as

Basic EPS (Q: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-32.267	-	0)	/	7.997
	=	-4.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-15.07

Athenex (FRA:2MT0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Athenex EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Athenex's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (FRA:2MT0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (FRA:2MT0) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Athenex (FRA:2MT0) Headlines

No Headlines